Age-related macular degeneration (AMD) is a complex and progressive degenerative eye disease resulting in severe loss of central vision. Recent evidence indicates that immune system dysregulation could contribute to the development of AMD. We hypothesize that defective lysosome-mediated clearance causes accumulation of waste products in the retinal pigmented epithelium (RPE), activating the immune system and leading to retinal tissue injury and AMD. We have generated unique genetically engineered mice in which lysosome-mediated clearance (both by phagocytosis and autophagy) in RPE cells is compromised, causing the development of features of early AMD. Our recent data indicate a link between lipocalin-2 (LCN-2) and the inflammatory responses induced in this mouse model. We show that nuclear factor-B (NF-B) and STAT-1 may function as a complex in our animal model system, together controlling the upregulation of LCN-2 expression in the retina and stimulating an inflammatory response. This study revealed increased infiltration of LCN-2-positive neutrophils in the choroid and retina of early AMD patients as compared with age-matched controls. Our results demonstrate that, both in our animal model and in human AMD, the AKT2-NF-B-LCN-2 signalling axis is involved in activating the inflammatory response, making this pathway a potential target for AMD treatment.
Introduction
Inflammation plays a key role in the pathogenesis of various age-related diseases, including age-related macular degeneration (AMD) [1] . Deregulation of the innate immune system is thought to be critical for the onset of AMD; complement has been implicated, and genetic studies show a strong association between AMD and polymorphisms in complement pathway genes [2, 3] . Furthermore, the activation of various cytokines/chemokines [4] and of the NLRP3 inflammasome have been invoked as being central to AMD pathogenesis [5] .
We have recently shown elevated levels of lipocalin-2 (LCN-2) in the RPE of aged mice lacking a lysosomal lumenal protein, βA3/A1-crystallin. Coupled with the associated increases in chemokine (C-C-motif) ligand 2 expression, reactive gliosis, and immune cell infiltration, it seems likely that LCN-2 plays a pivotal role in activating an inflammatory response in AMD [6] . A recent study showed LCN-2 to be a molecular target for reducing cellular stress during retinal degeneration [7] . Here, we provide novel evidence that the activation of inflammation in AMD is mediated through the AKT2-nuclear factor-κB (NF-κB)-LCN-2 signalling axis.
Materials and methods
The detailed methods are given in supplementary material, Supplementary materials and methods. experiments. Results are presented as mean ± standard deviation (SD) [8] .
Study approval
All procedures in this study involving human tissue were in accordance with the tenets of the Declaration of Helsinki, and were approved by the Institutional Review Boards of the Johns Hopkins University and University of Minnesota. All animal studies were conducted in accordance with the Guide for the Care and Use of Animals (National Academy Press), and were approved by the Animal Care and Use Committees of the Johns Hopkins University and Noble Life Sciences.
Results and discussion
Pro-inflammatory preference in an animal model of AMD Lack of a comprehensive animal model of AMD limits our understanding of the cellular mechanisms in the critical early stages of the disease. We have recently developed genetically engineered mouse models that show a slowly progressive AMD-like pathology associated with inefficient lysosomal clearance [8] . Altered lysosomal clearance can potentiate an inflammatory response and contribute to pathogenesis in various diseases [9] .
Lysosomal function declines with age, the rate varying among individuals. Individuals with greater loss of lysosomal clearance functions in the RPE during ageing may mount inflammatory responses to particular factors/triggers in the retina, leading to AMD. One such trigger could be LCN-2, an adipokine whose level is elevated in many inflammation-associated diseases, and which may contribute to the induction of inflammation in our model [6] . To test this hypothesis, we injected 4-month-old Cryba1 (gene encoding βA3/A1-crystallin) knockout (KO) and Cryba1 floxed control mice with Using a mouse immune array, we found clear pro-inflammatory responses in both retina and RPE extracts from Cryba1 KO mice treated with LPS, as compared with floxed control and untreated Cryba1 KO groups (supplementary material, Figure 1A , B). Western blots showed increased expression of the pro-inflammatory mediators interleukin (IL)-12 and inducible nitric oxide synthase (iNOS) and decreased expression of the anti-inflammatory mediators IL-10 and arginase-1 (Arg-1) ( Figure 1A ) in retinas from Cryba1 KO mice treated with LPS, as compared with the control and untreated Cryba1 KO groups. The heightened inflammatory state in the retinas of Cryba1 KO mice treated with LPS was further evidenced by increased microglial cell activation and polarization ( Figure 1B, C) . Microglial activation in the retina occurred concomitantly with activation of Müller cells ( Figure 1C) , a condition associated with reactive gliosis and an inflammatory response. The combination of increased pro-inflammatory mediator expression and microglial activation/polarization is critical for the onset of inflammatory processes in retinal diseases [11] . Our data indicated an inflammatory response that was most prominent in the retinas of the LPS-treated KO mice. We have previously shown that LCN-2 stimulates inflammation in the retina, particularly when the lysosomal-mediated clearance in the RPE is compromised [6] . Loss of Cryba1 diminishes lysosomal-mediated clearance in the RPE, resulting in increased expression of LCN-2 [6, 8] .
LCN-2 levels are increased in human AMD patients
We next investigated whether LCN-2 is also activated in human AMD patients. We assessed LCN-2 expression in human donor eyes: five age-matched normal control eyes, and nine AMD eyes graded for disease severity according to the Minnesota Grading System (MGS) (supplementary material, Table S1 ) [12] . Western blot data (Figure 2A ) confirmed that LCN-2 expression was significantly increased in early AMD (MGS2) as compared with age-matched controls (MGS1). Moreover, expression remained high in more advanced AMD (MGS3) and in donors with late AMD
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showing central geographical atrophy (MGS4). These studies suggest that LCN-2 could be a novel indicator of early AMD. Furthermore, immunostaining of human AMD tissue sections revealed LCN-2-positive infiltrating neutrophils in the retina and submacular choroid ( Figure 2B ). Neutrophils contribute to various inflammatory diseases, and higher levels of circulating neutrophils have been associated with AMD [13] . These data indicate a role for LCN-2 in activating inflammation in both human AMD and in our animal model, prompting us to evaluate how LCN-2 might induce inflammatory pathways in the pathogenesis of AMD.
Activation of the AKT2-NF-κB-LCN2 signalling axis in AMD
The LCN-2 promoter has binding sites for several transcription factors [14] . It has been reported that NF-κB regulates LCN-2 by binding to specific promoter sites during inflammatory stress [15] . This information prompted us to perform a chromatin immunoprecipitation (ChIP) study to identify NF-κB-binding sites in the LCN-2 promoter region in our mouse model. Interestingly, we found that, in retinas from Cryba1 KO mice (with or without LPS), the NF-κB p65 subunit was associated with a binding motif in the promoter region (−3171) of LCN-2 (Table 1 and Figure 2C ). This was not true in Cryba1 floxed retinas (with or without LPS). This suggests that NF-κB may regulate LCN-2 expression in our mouse model, thereby inducing inflammation. However, a previous study reported that STAT-1 binds to the −3171 promoter region of LCN-2 in adipocytes [15] . Further investigation with reverse ChIP analysis followed by immunoblotting with pSTAT-1 (S727) revealed an association between NF-κB and STAT-1 at the −3171 promoter binding site of LCN-2 in the LPS-treated Cryba1 KO retinas ( Figure 2D ). Our studies provide novel evidence that NF-κB and STAT-1 may function as a complex, thereby controlling the upregulation of LCN-2 in the retina and stimulating an inflammatory response. Such dual stimulation has been previously shown in the inflammatory responses of CXCL1 and CXCL2 to both NF-κB and STAT-1 [16] . We also observed increased nuclear translocation of NF-κB p65 and p50 subunits ( Figure 2E ), specifically as a heterodimer (supplementary material, Figure S2 ), in the retinas of LPS-treated Cryba1 KO mice, as compared with the control and untreated Cryba1 KO mice. A previous study [15] showed that interferon (IFN)-γ and tumour necrosis factor (TNF)-α induce STAT-1 and NF-κB, respectively, and that these transcription factors are required for LCN-2 activation. Our array data also show increases in both IFN-γ and TNF-α expression in Cryba1 KO mice treated with LPS (supplementary material, Figure S1 ).
To further delineate possible upstream regulators of NF-κB, we performed a human proteome high-throughput microarray assay, and found that βA3/A1-crystallin interacts with AKT2, a serine/threonine kinase. Through mass spectrometry analysis, we observed that pAKT2 is associated with βB2-crystallin in the mouse retina (supplementary material, Figure S3 ). βB2-crystallin was the strongest binding partner of βA3/A1-crystallin in the same array. In the lens, heterodimer formation between βA3-crystallin and βB2-crystallin is energetically favoured and important for transparency [17] . In the retina, the association between βB2-crystallin and βA3/A1-crystallin may regulate AKT2 phosphorylation in the presence of inflammatory stimuli. Lack of βA3/A1-crystallin in the Cryba1 KO mice would disrupt this particular association. AKT2 is directly associated with the phosphorylation of IKKα, which is required for activation of NF-κB during inflammatory stress [18] . As we have previously shown activation of LCN-2 in our ageing Cryba1 conditional KO mice [6] , a mouse model that shows a slowly progressing form of AMD-like pathology, we determined whether AKT2 and NF-κB are also activated. There was increased phosphorylation of AKT2, and there were increased levels of NF-κB and LCN-2, in retinas from 1-year-old Cryba1 conditional KO mice, as compared with floxed controls ( Figure 3A, B) . These results suggest that activation of the AKT2-mediated NF-κB signalling axis exerts a pro-inflammatory bias in the retina of our mouse model by upregulating expression of LCN-2. To confirm this, triciribine, a potent and selective inhibitor B). Furthermore, among human retina specimens, those from AMD patients showed increased expression of pAKT2 and NF-κB as compared with age-matched controls ( Figure 3C ). Taken together, our findings suggest that the AKT2-NF-κB-LCN-2 signalling axis represents a potential therapeutic target for AMD and that LCN-2 may be a novel indicator of early disease.
